Zuga Matt

CFO & Chief Business OfficerAcumen Pharmaceuticals, Inc. (ABOS) · full profile →Form 4 · filed Jan 7, 2026
Net Selling
Open-Market Buys
$0
Open-Market Sells
$29K
Net Open-Market Flow
-$29K
Transactions
4
4 non-derivative · 0 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Jan 7, 2026Sell(S)4K$2.00$8K219K
Jan 7, 2026Sell(S)2K$1.99$3K217K
Jan 6, 2026Sell(S)5K$1.97$10K223K
Jan 5, 2026Sell(S)4K$1.96$8K228K

Transaction Codes

S
Open-market sale

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001628280-26-001265) within minutes of acceptance. Every field above traces to the original document. Verify it directly: